Lee, M., Hong, S., Cho, Y., Rhee, H., Yu, M. H., Bae, J., . . . Cha, B. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: A 24-week, open-label, randomized controlled trial. BMC.
Chicago Style (17th ed.) CitationLee, Minyoung, et al. Synergistic Benefit of Thiazolidinedione and Sodium-glucose Cotransporter 2 Inhibitor for Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes: A 24-week, Open-label, Randomized Controlled Trial. BMC.
MLA (9th ed.) CitationLee, Minyoung, et al. Synergistic Benefit of Thiazolidinedione and Sodium-glucose Cotransporter 2 Inhibitor for Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes: A 24-week, Open-label, Randomized Controlled Trial. BMC.